• Created Market Access Plan (MAP) in preparation for launch; Developed preliminary product pricing strategy• Led development and testing of Payer Messaging strategy, in alignment with HCP Messaging• Co-led all interactions with G-BA and HAS, to gather formal HTA advice prior to Ph3 protocol lock• Provided commercial insights and guidance to Clinical and Regulatory teams to inform secondary Ph3 endpoints• Partnered with HEOR on value assessments and developing preliminary cost-per-QALY estimates

• Global Champion for the Integrated Access Strategy, the AbbVie standard for developing and communicating the Global Access Vision for every indication of every molecule• Served as GMAP representative on all AbbVie Future Fit committees and workstreams, with a particular focus on Global Brand Excellence (GBEx) and integrating Market Access into the 1-7-5 Global Brand Planning process• Lead for all internal GMAP meetings and comms, including chairing all GMAP-wide town hall meetings• Lead for American Access Academy (A³) project, elevating GMAP’s strategic vision of US reimbursement• Champion for GMAP Leads within all Global Value & Access Teams (VATs), elevating the Access perspective within the AbbVie Pipeline Commercialization Model (PCM)

• Global role supporting all Immunology Pipeline candidates, including follow-on indications for Skyrizi and Rinvoq,as well as first indications for ABBV-599, -154, -157, -323 and others• Crafted and delivered all Market Access elements of the Early Brand Plans for all indications of Skyrizi. Proactively asserted the role of GMAP in all Pipeline initiatives and discussions• Crafted and/or delivered Market Access responses within Senior Governance bodies, including PCC, LMG and TASC

• Global role supporting (sequentially) Humira Rheum and Humira Derm• Global Lead for the GMAP Negotiation Framework, developed to support the Skyrizi Ps launch. Also Global Lead for the PIVOTAL 2.0 project, digitally evolving the piece while adding guidance for on-market products• Global Lead for first ever GMAP AbbVie Care Value Prop, integrating the PASSION and NURTURE studies, in order to increase Payer-perceived value of the AbbVie Care patient support program

• Contributed to all global RA commercial strategic guidance, including Global Brand Plan, LRP, Affiliate Tactical Roadmap, and Affiliate Brand Plan reviews, with a particular focus on JAPAC Area. During this period, among the Top 16 Affiliates, Humira closed the RA share gap vs. market leader by >2%, while exceeding Global Plan in 2013, 2014, and 2015• Created and launched the EarlyScan project, using high-throughput ultrasound screenings to identify undertreated bionaive RA patients. Program adopted by 7 of the Top 10 Affiliates within 3 months of launch• Global Lead for the Treat to Target (T2T) program and the Targeted Ultrasound Initiative (TUI), dual cornerstones of the unbranded Standard of Care strategy• Global RA Lead for the Dose Tapering and Withdrawal (DT&W) project, which sought to identify both challenges and opportunities, within a market environment that will increasingly demand these treatment options. Team received a President’s Award for 2014

• Responsible for all Rheum Professional PsA tactics and projects in the US, including iPad apps, websites, and printed materials. During this period, Humira reduced the PsA share gap vs. market leader by >2%, while exceeding Plan in 2011, 2012, and 2013• Led all development and execution of Humira presence at ACR 2012 meeting in Washington DC. Responsibilities included all aspects of booth creation, as well as launch of new branded “Jeans” Professional Marketing campaign, resulting in 21% increase in booth traffic• Created the first ever iPad SpA Sales Aids leveraging the Adobe DPS e-publishing platform. Implementation, training, and deployment all identified as best practices; adopted by multiple US brand teams. Team received an Award USA for 2013• Pioneered SpA Imaging Satellite Symposium, using videoconferencing for the first time, to connect 54 locations to an interactive multi-KOL presentation on MRI, Ultrasound, and Radiography. Drove broader Imaging strategy, accelerating diagnosis of PsA and AS

• Global strategic role (WW, ex-US) in support of Abound (US brand name: Juven), a unique wound-healing nutritional supplement launched in 8 countries in 2010.• Spearheaded all development and execution for Abbott’s presence at the largest nutrition congress in Latin America: FELANPE 2010 in Asunción, Paraguay. Approved all budgets; coordinated ten LA affiliates; led week-long execution onsite• Selected all launch targets for Abound in Latin America. Generated LRP market-sizing estimates for each affiliate. Led all discussions and aligned with internal partners including Commercial (both Area and Affiliate), Medical, Regulatory, Legal, and Business Insights

• Led vendor in generating annual Attitudes, Awareness, and Usage (AAU) analysis of physician perception of all competitors in US dyslipidemia market• Managed team of analysts generating all weekly and monthly performance metrics, for both Niaspan and Simcor

• Carried the bag for four products in support of dyslipidemia portfolio, calling on physicians and delivering core messaging• Crafted physician segmentation strategy in preparation for TriLipix launch; created and optimized team routing plan; generated team performance analytics to optimize message reach• Contributed to successful launch of Simcor. At district sales meetings, selected to present overview of clinical research used to promote all Dyslipidemia products

• Developed Life Cycle Management (LCM) strategy for flagship blockbuster product's 2nd- and 3rd-generation launches; presented recommendations to senior management, identifying long-term strategy through 4Q12.• Designed and conducted quantitative market research, assessing Physician perceptions of unmet medical needs, as well as their reactions to multiple Target Product Profiles.

• Worked in a collaborative cross-functional matrix environment, aligning with colleagues in Commercial Development, Clinical Development, Statistical Analysis, Medical Communications, Clinical Records Management, Research Site Management, and others• Coordinated with this team of internal partners to produce Clinical Study Reports summarizing Phase 2 and 3 trials, for submission to FDA and EMA. Coordinated all activity through the creation of detailed MS Project plans• Promoted to lead team of four analysts across multiple worldwide sites, analyzing highest-priority compound in global R&D pipeline, a small-molecule CETP-inhibitor with total budgeted spend of $1.2B described by The New York Times as “The future of Pfizer”• Developed and delivered training to 100+ analysts on all reporting software and systems; recognized by senior management for skill in training

• Analyzed pharmaceutical clinical trials data for safety and efficacy, in support of $2m antihypertensive drug development study.